Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	$ 99,898	$ 80,992	$ 177,397	$ 157,364
Royalty revenue
Revenue Recognition and Collaboration Arrangements
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(6,912)	(6,912)
Total net royalty revenue	63,742	62,265	122,157	119,123
GSK
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	63,742	62,265	122,157	119,123
GSK | Royalty revenue
Revenue Recognition and Collaboration Arrangements
Royalties	67,198	65,721	129,069	126,035
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(6,912)	(6,912)
GSK | RELVAR/BREO
Revenue Recognition and Collaboration Arrangements
Royalties	53,980	54,454	106,118	105,337
GSK | ANORO
Revenue Recognition and Collaboration Arrangements
Royalties	$ 13,218	$ 11,267	$ 22,951	$ 20,698